Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Total Liabilities (2023 - 2025)

Connect Biopharma Holdings' Total Liabilities history spans 3 years, with the latest figure at $12.0 million for Q3 2025.

  • For Q3 2025, Total Liabilities rose 111.91% year-over-year to $12.0 million; the TTM value through Sep 2025 reached $12.0 million, up 111.91%, while the annual FY2024 figure was $9.1 million, 64.77% down from the prior year.
  • Total Liabilities for Q3 2025 was $12.0 million at Connect Biopharma Holdings, up from $11.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $25.9 million in Q4 2023 and bottomed at -$110.9 million in Q2 2024.
  • The 3-year median for Total Liabilities is $9.5 million (2024), against an average of -$29.7 million.
  • The largest annual shift saw Total Liabilities crashed 64.77% in 2024 before it skyrocketed 111.91% in 2025.
  • A 3-year view of Total Liabilities shows it stood at $25.9 million in 2023, then plummeted by 64.77% to $9.1 million in 2024, then surged by 31.5% to $12.0 million in 2025.
  • Per Business Quant, the three most recent readings for CNTB's Total Liabilities are $12.0 million (Q3 2025), $11.4 million (Q2 2025), and $9.8 million (Q1 2025).